APOA1 and ovarian carcinoma: But, the four-biomarker panel (CA125 plus transthyretin plus apolipoprotein A1 plus hemoglobin) did not improve the overall sensitivity and specificity for discriminating between ovarian cancer and healthy individuals (and/or benign group) as compared to the three-biomarker panel in the ROC curve.